biosimilar Archives -

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

News/ News/ Sales and Marketing

Novartis takes aim at MS blockbuster Tysabri in US and Europe

Phil Taylor Biogen, biosimilar, Novartis, Sandoz, Tysabri 0 Comment

Regulators in the US and Europe have started to review Novartis’ biosimilar version of Biogen’s big-selling multiple sclerosis

Novartis takes aim at MS blockbuster Tysabri in US and Europe

https://pharmaphorum.com/news/novartis-takes-aim-at-ms-blockbuster-tysabri-in-us-and-europe/

News/ News/ Sales and Marketing

Polpharma in pole position for biosimilar Tysabri in Europe

Phil Taylor Biogen, biosimilar, Polpharma, Sandoz, Tysabri 0 Comment

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version

Polpharma in pole position for biosimilar Tysabri in Europe

https://pharmaphorum.com/news/polpharma-in-pole-position-for-biosimilar-tysabri-in-europe/

News/ News/ Sales and Marketing

Civica plans shake-up of insulin sector with low-cost biosimilars

Phil Taylor biosimilar, Civica, Eli Lilly, insulin, Novo Nordisk, pricing, Sanofi 0 Comment

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US

Civica plans shake-up of insulin sector with low-cost biosimilars

https://pharmaphorum.com/news/civica-plans-shake-up-of-insulin-sector-with-low-cost-biosimilars/

News/ News/ Sales and Marketing

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

Phil Taylor Biocon, biosimilar, M&A, Viatris 0 Comment

India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

https://pharmaphorum.com/news/biocon-buys-viatris-biosimilars-for-3-3bn-eyes-ipo/

News/ News/ Sales and Marketing

FDA clears first “interchangeable” Humira biosimilar

Phil Taylor AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval 0 Comment

Biosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA

FDA clears first “interchangeable” Humira biosimilar

https://pharmaphorum.com/news/fda-clears-first-interchangeable-humira-biosimilar/

News/ News/ Sales and Marketing

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

Phil Taylor biosimilar, Byooviz, Lucentis, Novartis, ophthalmology, Roche, Samsung Bioepis, wet AMD 0 Comment

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

https://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/

Market Access/ News/ News

FDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilar

Phil Taylor biosimilar, fda, interchangeable, Lantus, Mylan, Sanofi, US 0 Comment

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is

FDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilar

https://pharmaphorum.com/news/fda-okays-mylan-insulin-drug-as-first-interchangeable-biosimilar/

Market Access/ Views & Analysis/ Views and analysis

The US biosimilar market: Predictions for 2021

mike.hammerton@pharmaphorum.com 2021, AmerisourceBergen, biosimilar, reimbursement, US market 0 Comment

It has been five years since the first biosimilar launched in the United States market—marking the first steps

The US biosimilar market: Predictions for 2021

https://pharmaphorum.com/views-and-analysis/biosimilar-market-predictions-2021/

Trending

biosimilar

Login